Real‐world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV ‐1 sub‐subtype A6 harbouring the L74I mutation
HIV Medicine · 2025
DOI: 10.1111/hiv.70073 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, 2025. Verfasst von Elena Orlova-Morozova und 6 weiteren Autor:innen. Beteiligte Einrichtung: Moscow Regional AIDS Center, Moscow Region, Kotelniki, Russia. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Emtricitabine, Tenofovir. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Objectives
This study aimed to evaluate the effectiveness of bictegravir (BIC)‐based antiretroviral therapy (ART) against HIV‐1 sub‐subtype A6 viruses carrying the L74I polymorphic mutation in integrase.
Methods
A total of 100 ART‐naive people living with HIV from the Moscow Regional AIDS Center were enrolled between May and July 2023. HIV‐1 subtypes and baseline drug resistance mutations were analysed prior to treatment initiation. All patients began a first‐line ART regimen and were followed for 40–48 weeks, at which point viral load (VL) was assessed.
Results
HIV‐1 sub‐subtype A6 was identified in 78% of people living with HIV; among these, the L74I mutation was present in 97.3%. Of those carrying the mutation, only one patient experienced treatment failure, attributed to very low adherence.
Conclusions
The BIC/FTC/TAF regimen is fully effective in treatment‐naive people living with HIV infected with HIV‐1 sub‐subtype A6 harbouring the L74I integrase mutation. These findings support the continued use of second‐generation integrase strand transfer inhibitor (INSTI)‐based regimens for individuals with this HIV‐1 subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Moscow Regional AIDS Center, Moscow Region, Kotelniki, Russia.
- Central Research Institute of Epidemiology, Moscow, Russia.
- Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia.
- Gamaleya National Research Center of Epidemiology and Microbiology, Moscow, Russia.
ORCID-Profile: Anastasiya Antonova, Rafael Yapparov, Marina Bobkova
Förderung
- Russian Science Foundation
Zitieren
APA
Orlova-Morozova, E., Kireev, D., Kirichenko, A., Bobkov, V., Antonova, A., Yapparov, R., & Bobkova, M. (2025). Real‐world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV ‐1 sub‐subtype A6 harbouring the L74I mutation. HIV Medicine. https://doi.org/10.1111/hiv.70073
Vancouver
Orlova-Morozova E, Kireev D, Kirichenko A, Bobkov V, Antonova A, Yapparov R, et al. Real‐world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV ‐1 sub‐subtype A6 harbouring the L74I mutation. HIV Medicine. 2025. doi:10.1111/hiv.70073
BibTeX
@article{OrlovaMorozova2025,
author = {Orlova-Morozova, Elena and Kireev, Dmitry and Kirichenko, Alina and Bobkov, Vyacheslav and Antonova, Anastasiya and Yapparov, Rafael and Bobkova, Marina},
title = {Real‐world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV ‐1 sub‐subtype A6 harbouring the L74I mutation},
journal = {HIV Medicine},
year = {2025},
doi = {10.1111/hiv.70073}
}
EUVIMED